JP2017513516A5 - - Google Patents

Download PDF

Info

Publication number
JP2017513516A5
JP2017513516A5 JP2017501094A JP2017501094A JP2017513516A5 JP 2017513516 A5 JP2017513516 A5 JP 2017513516A5 JP 2017501094 A JP2017501094 A JP 2017501094A JP 2017501094 A JP2017501094 A JP 2017501094A JP 2017513516 A5 JP2017513516 A5 JP 2017513516A5
Authority
JP
Japan
Prior art keywords
microorganism
cancer
recombinant chimeric
group
chimeric adi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017501094A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017513516A (ja
JP6612316B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/021189 external-priority patent/WO2015143006A1/en
Publication of JP2017513516A publication Critical patent/JP2017513516A/ja
Publication of JP2017513516A5 publication Critical patent/JP2017513516A5/ja
Application granted granted Critical
Publication of JP6612316B2 publication Critical patent/JP6612316B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017501094A 2014-03-18 2015-03-18 操作されたキメラpeg化adi及び使用方法 Active JP6612316B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461954929P 2014-03-18 2014-03-18
US61/954,929 2014-03-18
PCT/US2015/021189 WO2015143006A1 (en) 2014-03-18 2015-03-18 Engineered chimeric pegylated adi and methods of use

Publications (3)

Publication Number Publication Date
JP2017513516A JP2017513516A (ja) 2017-06-01
JP2017513516A5 true JP2017513516A5 (https=) 2018-04-26
JP6612316B2 JP6612316B2 (ja) 2019-11-27

Family

ID=54145261

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017501094A Active JP6612316B2 (ja) 2014-03-18 2015-03-18 操作されたキメラpeg化adi及び使用方法

Country Status (7)

Country Link
US (1) US10463721B2 (https=)
EP (1) EP3119421B1 (https=)
JP (1) JP6612316B2 (https=)
KR (2) KR102523031B1 (https=)
CN (1) CN106794229B (https=)
SG (1) SG11201607736UA (https=)
WO (1) WO2015143006A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3744341A1 (en) 2013-03-15 2020-12-02 TDW Group Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
KR102523031B1 (ko) 2014-03-18 2023-04-19 티디더블유 그룹 조작된 키메라성 페길화된 adi 및 사용 방법
JP6782230B2 (ja) * 2014-09-16 2020-11-11 ティーディーダブリュー グループ 癌治療のためのadi−peg20抗体に対する交差反応性が低減したアルギニンデイミナーゼ
TWI847958B (zh) 2016-07-05 2024-07-11 英屬開曼群島商北極星藥業集團股份有限公司 用精胺酸耗盡劑進行之組合癌症免疫療法
TWI784982B (zh) * 2016-11-02 2022-12-01 開曼群島商北極星藥業集團股份有限公司 聚乙二醇化精胺酸脫亞胺酶之調配物
CN106591270B (zh) * 2017-01-23 2018-09-21 江南大学 一株定点突变改造的基因工程精氨酸脱亚胺酶
TWI911136B (zh) * 2017-03-29 2026-01-11 開曼群島商北極星藥業集團股份有限公司 蛋白質結合物
WO2020009740A2 (en) 2018-04-25 2020-01-09 Washington University Compositions and methods of use thereof for treatment of metabolic diseases and related disorders
WO2022063178A1 (en) * 2020-09-23 2022-03-31 The Hong Kong Polytechnic University Fluorescent biosensor for rapid determination of l-arginine
KR102640230B1 (ko) * 2021-09-24 2024-02-22 가천대학교 산학협력단 C-peptide를 처리한 자궁내막 기질세포의 이동성 변화 기작을 이용한 자궁내막 관련질환의 진단 방법 및 자궁내막 관련질환 치료제의 스크리닝 방법
CN120153071A (zh) * 2022-09-02 2025-06-13 波拉里集团 修饰之精氨酸脱亚胺酶

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2900279B2 (ja) 1989-08-02 1999-06-02 株式会社ジャパンエナジー 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤
US5372942A (en) 1992-02-10 1994-12-13 Coriell Institute For Medical Research Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent
US5804183A (en) 1997-01-31 1998-09-08 Enzon, Inc. Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
US6635462B1 (en) * 1997-05-12 2003-10-21 Phoenix Pharmacologies, Inc. Mutated form of arginine deiminase
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US6180387B1 (en) 1997-08-11 2001-01-30 Smithkline Beecham Corporation Arginine deiminase
IT1298918B1 (it) 1998-02-20 2000-02-07 Mendes Srl Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche
WO2002009741A1 (en) 2000-07-27 2002-02-07 Angiolab, Inc. The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis
WO2002044360A2 (en) * 2000-11-28 2002-06-06 Phoenix Pharmacologics, Inc. Modified arginine deiminase
AU2003282883B2 (en) 2002-11-18 2008-12-04 Polaris Group Methods for inhibiting viral replication in vivo
WO2004097051A2 (en) 2003-04-29 2004-11-11 Wyeth Methods for diagnosing aml and mds differential gene expression
WO2005052145A2 (en) * 2003-10-07 2005-06-09 University Of Florida Recombinant alkaliizing bacteria
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
WO2009006590A2 (en) 2007-07-04 2009-01-08 Dr. Reddy's Laboratories Ltd. Docetaxel process and polymorphs
US20090238813A1 (en) 2007-12-28 2009-09-24 Board Of Regents, The University Of Texas System Compositions And Methods For Engineered Human Arginine Deiminases
WO2010083312A2 (en) 2009-01-14 2010-07-22 The Trustees Of The University Of Pennsylvania Micro-rna biomarker in cancer
WO2011053871A2 (en) 2009-10-30 2011-05-05 Life Technologies Corporation Multi-primer assay for mycoplasma detection
WO2011151704A2 (en) 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
WO2012075173A2 (en) 2010-12-01 2012-06-07 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
US8663967B2 (en) 2011-08-22 2014-03-04 Jiangsu T-Mab Biopharma Co., Ltd. Arginine deiminase mutant and preparation and application thereof
EP3782653B1 (en) 2012-04-04 2025-03-19 Polaris Group Composition comprising pegylated arginine deiminase
EP3744341A1 (en) * 2013-03-15 2020-12-02 TDW Group Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
KR102523031B1 (ko) 2014-03-18 2023-04-19 티디더블유 그룹 조작된 키메라성 페길화된 adi 및 사용 방법
JP6782230B2 (ja) 2014-09-16 2020-11-11 ティーディーダブリュー グループ 癌治療のためのadi−peg20抗体に対する交差反応性が低減したアルギニンデイミナーゼ

Similar Documents

Publication Publication Date Title
JP2017513516A5 (https=)
RU2015141932A (ru) Аргининдеиминаза с пониженной перекрестной реактивностью к антителам adi-peg 20 для лечения рака
JP2016519069A5 (https=)
Yin et al. Reconfiguring the architectures of cationic helical polypeptides to control non-viral gene delivery
JP6243452B2 (ja) アルブミン結合アルギニンデイミナーゼ融合たんぱく質を含有する医薬組成物
JP2013509861A5 (https=)
JP2017006120A5 (https=)
JP2017529366A5 (https=)
RU2018131636A (ru) Новые конъюгаты аманитина
JP2019531093A5 (https=)
Ranji et al. Targeting cancer stem cell-specific markers and/or associated signaling pathways for overcoming cancer drug resistance
JP2016535009A5 (https=)
JP2017523781A5 (https=)
JP2013515745A5 (https=)
US10202421B2 (en) Tumor-targeting compounds
HRP20140947T1 (hr) Enzimska terapija raka
Pourhadi et al. Expression, purification, and cytotoxic evaluation of IL24-BR2 fusion protein
MX2020006671A (es) Proteinas de fusion.
Hu et al. Targeted modification of the cationic anticancer peptide HPRP-A1 with iRGD to improve specificity, penetration, and tumor-tissue accumulation
WO2008100482A3 (en) Peptides that target to tumor blood vessels of lung cancer and applications thereof
Ghavimi et al. Exploring the potential of anticancer peptides as therapeutic agents for cancer treatment
MX2012011668A (es) Peptidos cdca5 y vacunas que incluyen los mismos.
WO2015053413A1 (ja) ドライバーオンコジーンの遺伝子変異を標的にアルキル化する新規アルキル化剤
JP2022516054A5 (https=)
JP2017523783A5 (https=)